CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

Oritinib

Small moleculeexperimental

Clinical trial activity

8 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Apr 25, 2018 (NCT03603262)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C=CC(=O)Nc1cc(Nc2nccc(-c3c4n(c5ccccc35)CCCC4)n2)c(OC)cc1N(C)CCN(C)C
Mol. weight
539.68 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sh-1028

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06080776Phase 3May 11, 2023Huazhong University of Science and Technology, Nanjing Medical University, Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT04808648Phase 1Apr 6, 2021Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT04810533Phase 1May 13, 2020Nanjing Medical University, Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT04239833Phase 3Jan 31, 2020Huazhong University of Science and Technology, Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT03973632Phase 1Jul 31, 2019Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT03823807Phase 2Mar 31, 2019Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT03618043Phase 1Sep 30, 2018Huazhong University of Science and Technology, Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT03603262Phase 1Apr 25, 2018Nanjing Medical University, Nanjing Sanhome Pharmaceutical, Co., Ltd.
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Nanjing Sanhome Pharmaceutical, Co., Ltd.For profit8832018
Huazhong University of Science and TechnologyAcademic/Hospital3022018
Nanjing Medical UniversityAcademic/Hospital3022018
3 organizations
Page 1 / 1